Stockscreener 앱 받기
20.41
0.15%
-0.01
전일 마감가:
$20.40
열려 있는:
$20.42
하루 거래량:
117.65K
Relative Volume:
0.12
시가총액:
$598.62M
수익:
$17.16M
순이익/손실:
$-163.62M
주가수익비율:
-3.3569
EPS:
-6.08
순현금흐름:
$-121.61M
1주 성능:
+3.98%
1개월 성능:
+6.87%
6개월 성능:
+7.21%
1년 성능:
-20.02%
1일 변동 폭
$19.98
$20.73
1주일 범위
$19.20
$21.14
52주 변동 폭
$12.21
$41.31
Anaptysbio Inc Stock (ANAB) Company Profile
명칭
Anaptysbio Inc
전화
858-362-6295
주소
10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO, CA
ANAB을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ANAB
Anaptysbio Inc
|
20.38 | 575.27M | 17.16M | -163.62M | -121.61M | -6.08 |
|
ONC
Beigene Ltd Adr
|
228.48 | 25.49B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
432.77 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.2256 | 38.69M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
587.88 | 59.13B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
69.89 | 5.64B | 0 | -153.72M | -103.81M | -2.00 |
Anaptysbio Inc Stock (ANAB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-04 | 개시 | Wolfe Research | Outperform |
| 2024-12-11 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2024-12-02 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2024-07-22 | 개시 | H.C. Wainwright | Buy |
| 2024-07-19 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2024-04-16 | 개시 | Leerink Partners | Outperform |
| 2024-04-11 | 개시 | Wells Fargo | Overweight |
| 2024-03-12 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2024-02-26 | 개시 | BTIG Research | Buy |
| 2024-02-21 | 개시 | Stifel | Buy |
| 2024-02-16 | 개시 | Piper Sandler | Overweight |
| 2023-05-22 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2023-05-18 | 개시 | TD Cowen | Outperform |
| 2023-01-06 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2022-11-01 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2022-09-19 | 재개 | H.C. Wainwright | Buy |
| 2022-09-13 | 다운그레이드 | Truist | Buy → Hold |
| 2022-09-01 | 개시 | Raymond James | Outperform |
| 2022-03-22 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-06-22 | 개시 | H.C. Wainwright | Buy |
| 2021-05-21 | 개시 | UBS | Neutral |
| 2021-03-16 | 업그레이드 | Truist | Hold → Buy |
| 2021-03-09 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2021-03-08 | 다운그레이드 | JP Morgan | Overweight → Underweight |
| 2021-02-11 | 업그레이드 | JP Morgan | Underweight → Overweight |
| 2020-10-27 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2020-10-14 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2019-11-08 | 다운그레이드 | JP Morgan | Overweight → Underweight |
| 2019-11-08 | 다운그레이드 | Jefferies | Buy → Hold |
| 2019-11-08 | 다운그레이드 | SunTrust | Buy → Hold |
| 2019-11-08 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2019-06-21 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2019-06-21 | 다운그레이드 | Stifel | Buy → Hold |
| 2018-12-20 | 개시 | H.C. Wainwright | Buy |
| 2018-11-21 | 개시 | JP Morgan | Overweight |
| 2018-07-19 | 개시 | Credit Suisse | Outperform |
| 2018-04-04 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2018-03-27 | 재확인 | Stifel | Buy |
| 2018-03-06 | 재확인 | Stifel | Buy |
| 2018-02-15 | 재확인 | SunTrust | Buy |
| 2018-01-23 | 재확인 | Credit Suisse | Outperform |
| 2017-11-15 | 개시 | SunTrust | Buy |
| 2017-11-09 | 개시 | Jefferies | Buy |
| 2017-10-11 | 재확인 | RBC Capital Mkts | Outperform |
| 2017-09-15 | 개시 | RBC Capital Mkts | Outperform |
모두보기
Anaptysbio Inc 주식(ANAB)의 최신 뉴스
AnaptysBio Reports Strong Q1 2025 Results and Progress - TipRanks
AnaptysBio, Inc. (NASDAQ:ANAB) Shares Bought by Tower Research Capital LLC TRC - Defense World
Wells Fargo & Company MN Cuts Stake in AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat
AnaptysBio, Inc. (NASDAQ:ANAB) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Bridgefront Capital LLC Acquires New Holdings in AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat
Fairmount Funds Management LLC Makes New Investment in AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat
Q2 EPS Estimates for AnaptysBio Raised by Leerink Partnrs - MarketBeat
Granahan Investment Management LLC Buys New Shares in AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat
HC Wainwright Has Pessimistic View of AnaptysBio Q2 Earnings - MarketBeat
Anaptys Announces First Quarter 2025 Financial Results and Provides Business Update - ADVFN
AnaptysBio, Inc. (ANAB): Among the Unstoppable Growth Stocks to Invest in Now - Yahoo Finance
AnaptysBio (NASDAQ:ANAB) Posts Quarterly Earnings Results, Beats Estimates By $0.02 EPS - MarketBeat
AnaptysBio (NASDAQ:ANAB) Given New $54.00 Price Target at Guggenheim - MarketBeat
AnaptysBio, Inc. (NASDAQ:ANAB) Shares Purchased by Barclays PLC - MarketBeat
(ANAB) Investment Report - news.stocktradersdaily.com
Invesco Ltd. Sells 28,002 Shares of AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat
Susquehanna Fundamental Investments LLC Makes New Investment in AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat
Earnings Update: AnaptysBio, Inc. (NASDAQ:ANAB) Just Reported And Analysts Are Boosting Their Estimates - simplywall.st
Analysts Are Upgrading AnaptysBio, Inc. (NASDAQ:ANAB) After Its Latest Results - Yahoo Finance
Is AnaptysBio (NASDAQ:ANAB) Using Debt Sensibly? - simplywall.st
AnaptysBio First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Boxer Capital Management LLC Purchases New Shares in AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat
Nebula Research & Development LLC Makes New $231,000 Investment in AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat
AnaptysBio (ANAB) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
AnaptysBio Inc (ANAB) Q1 2025 Earnings: Revenue Surges to $27.8M - GuruFocus
AnaptysBio Inc (ANAB) Q1 2025 Earnings: Revenue Surges to $27.8M, Beating Estimates; EPS at -$1.28, Slightly Below Expectations - GuruFocus
Forecasting The Future: 6 Analyst Projections For AnaptysBio - Benzinga
AnaptysBio (ANAB) Price Target Raised by Guggenheim | ANAB Stock News - GuruFocus
AnaptysBio (ANAB) Price Target Increased Amid Promising Clinical Developments | ANAB Stock News - GuruFocus
Anaptys Announces First Quarter 2025 Financial Results and Provi - GuruFocus
AnaptysBio, Inc. (ANAB) Tops Q1 EPS by 2c - StreetInsider
AnaptysBio, Inc. (ANAB) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
AnaptysBio (ANAB) Surpasses Revenue Expectations with Strong Q1 Performance | ANAB Stock News - GuruFocus
ANAPTYSBIO, INC SEC 10-Q Report - TradingView
BRIEF-AnaptysBio Q1 Net Income USD -39.329 Million - TradingView
Anaptys Breakthrough: Rosnilimab Shows Strong Phase 2b Results in RA, Multiple Pipeline Catalysts Ahead - Stock Titan
AnaptysBio, Inc. (NASDAQ:ANAB) Shares Sold by Invesco Ltd. - Defense World
First Light Asset Management LLC Has $11.50 Million Stake in AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat
Wedbush Reaffirms “Outperform” Rating for AnaptysBio (NASDAQ:ANAB) - Defense World
AnaptysBio, Inc. (NASDAQ:ANAB) Shares Purchased by Geode Capital Management LLC - MarketBeat
JPMorgan Chase & Co. Has $1.52 Million Position in AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat
AnaptysBio Gears Up For Key Trial Readouts In Rheumatoid Arthritis And Lung Cancer - RTTNews
AnaptysBio (ANAB) Stock Maintains Outperform Rating with $40 Pri - GuruFocus
Anaptysbio Inc (ANAB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Anaptysbio Inc 주식 (ANAB) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| EcoR1 Capital, LLC | Director |
Dec 30 '24 |
Buy |
12.92 |
65,184 |
842,060 |
7,860,180 |
| EcoR1 Capital, LLC | Director |
Dec 31 '24 |
Buy |
12.93 |
13,268 |
171,513 |
7,873,448 |
| EcoR1 Capital, LLC | Director |
Jan 02 '25 |
Buy |
12.95 |
6,646 |
86,070 |
7,880,094 |
| RENTON HOLLINGS | Director |
Nov 29 '24 |
Option Exercise |
6.93 |
10,000 |
69,300 |
11,950 |
| RENTON HOLLINGS | Director |
Nov 29 '24 |
Sale |
25.00 |
10,000 |
250,000 |
1,950 |
3.08%
5.06%
자본화:
|
볼륨(24시간):